Bookmark

Add to MyYahoo RSS

Imitrex, Sumatriptan News

News on Imitrex, Sumatriptan (generic) continually updated from thousands of sources around the net.

Wednesday Aug 27 | PR-inside.com

New Market Research Report: Suda Ltd (SUD) - Financial and Strategic SWOT Analysis Review

The company develops and markets drugs for various diseases. Its products include ArTiMist, SUD-001, SUD-002, SUD-003, SUD-004, and SUD-005.

Comment?

Related Topix: Medicine, Malaria, Health, Migraine, Nausea, Vomiting, Erectile Dysfunction

Wed Aug 20, 2014

Hispanic Business

Pozen Inc /NC Files (8-K) Disclosing Entry into a Material Definitive Agreement

Immediately following the closing of the Divestiture, Amendment No. 1 to the Agreement between , entered into a Second Amendment to the Agreement which permits Worrigan, the assignee of Pernix's rights under the Agreement, to further assign the Agreement without prior written consent as collateral security for the benefit of purchasers of debt ... (more)

Comment?

Related Topix: Medicine

Hispanic Business

POZEN Announces U.S. Rights For TREXIMET Have Been Acquired by Pernix Therapeutics

The previously announced transaction was contingent upon Pernix securing financing, which is now complete.

Comment?

Related Topix: Biotech, Medicine, Pozen, Healthcare Industry, GlaxoSmithKline, Migraine, Health

Tue Aug 12, 2014

Naples Daily News

Pharmacist: Drugs and the domino effect When I graduated from...

When I graduated from pharmacy school in 1989, I was eager to ease the world's suffering.

Comment?

Related Topix: Flexeril, Cyclobenzaprine (generic), Medicine, Health, Pain, Vitamin B12, Supplement

Thu Aug 07, 2014

Hispanic Business

POZEN Reports Second Quarter 2014 Results

As part of the expense control, the Company has reduced its R&D staff and other costs and will continue to reduce costs not required to support the ongoing business activities.

Comment?

Related Topix: Biotech, Pozen, Healthcare Industry, Naproxen (generic), Aleve, Naprosyn, GlaxoSmithKline, Aspirin (generic), Bayer, Alka-Seltzer

Wed Aug 06, 2014

BioSpace

AVANIR Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial And Business Update

"We had a great quarter across all aspects of our business. I am delighted with the positive outcome of our ANDA patent litigation, solid revenue growth of 45% year-over-year, and the positive interim data from our open label PRISM II study in PBA and COMPASS clinical trial in migraine," said , president and CEO of Avanir.

Comment?

Related Topix: Biotech, Medicine, AVANIR Pharmaceuticals, Healthcare Industry, Healthcare Law, Law, Migraine, Health, Alzheimer's, Food and Drug Administration

Mon Aug 04, 2014

BioSpace

Closing For Pernix Therapeutics, Inc. Transaction To Acquire...

Pernix Therapeutics Holdings, Inc. , a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to TreximetA for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product.

Comment?

Related Topix: Medicine, Migraine, Health

•••
•••
•••
•••
•••
•••
•••